Shimetani Naoto
Department of Clinical Pathology, Koshigaya Hospital Dokkyo University School of Medicine, Koshigaya 343-8555.
Rinsho Byori. 2002 May;50(5):474-8.
Emerging and reemerging infectious diseases, drug-resistant bacteria and nosocomial infection are becoming increasingly serious social problems. To control infectious diseases, it is important to develop effective therapies and to achieve complete prevention of pathogen transmission. For these purposes, rapid detection of pathogenic microorganisms is essential. Recent development and technical innovation in laboratory tests and diagnosis for infectious diseases are remarkable. New techniques such as antigen detection and genetic diagnosis, neither of which require conventional culture, have been intensively developed and introduced into clinical practice. These methods are now widely accepted as effective diagnostic tools because of their high specificity, high sensitivity and rapidity. In this article, we describe the burden of medical expenses under the law on novel infectious diseases and medical reimbursement for diagnostic tests for these diseases.
新发和再发传染病、耐药菌以及医院感染正日益成为严重的社会问题。为控制传染病，开发有效的治疗方法并实现病原体传播的完全预防至关重要。为此，快速检测致病微生物必不可少。传染病实验室检测和诊断方面的最新进展和技术创新十分显著。诸如抗原检测和基因诊断等新技术已得到深入开发并引入临床实践，这两种技术均无需传统培养。由于其高特异性、高灵敏度和快速性，这些方法现已被广泛认可为有效的诊断工具。在本文中，我们描述了根据新发传染病相关法律产生的医疗费用负担以及这些疾病诊断检测的医疗报销情况。
